RGMa-Inhibiting Agent for Abnormal Protein Aggregate Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively inhibit the accumulation of abnormal protein aggregates, which are a hallmark of neurodegenerative diseases such as frontotemporal lobar degeneration, leading to progressive neurodegeneration and cognitive impairment.
Innovation Solution
An agent comprising an RGMa inhibiting substance, particularly an anti-RGMa neutralizing antibody, is developed to inhibit the accumulation of abnormal protein aggregates and prevent or treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used, then treatment of neurodegenerative diseases is attempted, but they fail to effectively inhibit the accumulation of abnormal protein aggregates
Solution Approach 1:
The patent introduces RGMa inhibiting substances as intermediary agents that mediate between the therapeutic goal and the pathological process. These substances specifically target RGMa to prevent its interaction with abnormal proteins, thereby inhibiting aggregate accumulation without directly confronting the aggregates themselves. This intermediary approach resolves the contradiction by providing a reliable therapeutic mechanism that effectively addresses the harmful accumulation through indirect intervention.
Solution Approach 2:
The invention extracts and targets the specific molecular mechanism (RGMa) that mediates abnormal protein aggregate accumulation. By identifying and inhibiting RGMa as the key extractor of this pathological process, the therapy can selectively remove or block the harmful mechanism without affecting other cellular functions. This extraction principle resolves the contradiction by isolating and addressing the specific cause of aggregate accumulation.
2Object-generated harmful factors
If RGMa inhibiting substance is administered, then accumulation of abnormal protein aggregates is inhibited, but potential side effects and drug development challenges arise
Solution Approach 1:
The patent employs RGMa inhibiting substances that serve multiple functions: they inhibit RGMa-mediated aggregate accumulation, prevent neuronal uptake of abnormal proteins, and potentially address multiple types of neurodegenerative diseases simultaneously. This multi-functionality reduces drug development complexity by using a single agent to address multiple pathological aspects, thereby resolving the contradiction between effectiveness and development complexity.
3Reliability
If RGMa inhibiting substance is used, then neuronal health is preserved, but long-term safety and efficacy need further validation
Solution Approach 1:
The patent employs RGMa inhibiting substances that act preliminarily to prevent the formation and accumulation of abnormal protein aggregates before they can cause significant neuronal damage. By intervening early in the pathological process, the therapy preserves neuronal health and prevents disease progression. This preliminary action approach addresses the contradiction by establishing protective effects that can be maintained over the long term through continuous or periodic administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent effectively reduces the accumulation of abnormal protein aggregates, preserving neuronal health and potentially treating conditions like frontotemporal dementia and other neurodegenerative disorders.
Implementation Method 1
an anti-RGMa neutralizing antibody has the effect of inhibiting the accumulation of abnormal protein aggregates
Data Source
Figure 1(A)~1(B)
Figure 2(A)~2(B)
Figure 3(A)~3(C)
AI summary
Provided is an agent for inhibiting abnormal protein aggregate accumulation or an agent for inhibiting the uptake of an abnormal protein into a neuron, particularly an agent for preventing or treating a disease associated with accumulation of abnormal protein aggregates, in which the agent contains an RGMa inhibiting substance.